Sugi Predict

Sugi Predict / Compounds / SCHEMBL9980671

SCHEMBL9980671

SCHEMBL9980671

C[C@@H](NC(=O)[C@@H](C)NC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.50
▸ CTSK P43235 7/20 0.46
▸ CTSS P25774 6/20 0.46
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ CA7 P43166 1/20 0.46
▸ MEN1 O00255 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ CTSL P07711 1/20 0.44
▸ CTSB P07858 1/20 0.44
▸ GLS O94925 1/20 0.42
▸ CYP2D6 P10635 1/20 0.41
▸ GLA P06280 1/20 0.41
▸ ATM Q13315 1/20 0.40
▸ MME P08473 1/20 0.40
▸ ACE P12821 1/20 0.40
▸ CPA1 P15085 1/20 0.40
▸ ACE2 Q9BYF1 1/20 0.40
▸ CA12 O43570 1/20 0.39
▸ CA14 Q9ULX7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17664986 1.00 KMT2A (0.50) KMT2ACTSKCTSSCA1CA2
SCHEMBL10607843 1.00 KMT2A (0.50) KMT2ACTSKCTSSCA1CA2
SCHEMBL9980754 1.00 KMT2A (0.50) KMT2ACTSKCTSSCA1CA2
SCHEMBL30471514 1.00 KMT2A (0.50) KMT2ACTSKCTSSCA1CA2
SCHEMBL7057277 1.00 KMT2A (0.50) KMT2ACTSKCTSSCA1CA2
SCHEMBL7439787 1.00 KMT2A (0.50) KMT2ACTSKCTSSCA1CA2
SCHEMBL30471384 1.00 KMT2A (0.50) KMT2ACTSKCTSSCA1CA2
SCHEMBL6891888 1.00 KMT2A (0.50) KMT2ACTSKCTSSCA1CA2
SCHEMBL148100 0.92 CA1 (0.52) KMT2ACTSKCTSSCA1CA2
SCHEMBL148099 0.92 CA1 (0.52) KMT2ACTSKCTSSCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503452-B2 Antimicrobial compounds and methods CURZA GLOBAL, LLC (US) 2025-12-23 — — US disclosed
US-20240043379-A1 PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2024-02-08 — — US disclosed
US-11685714-B2 Prodrugs of cytotoxic active agents having enzymatically cleavable groups BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2023-06-27 — — US disclosed
US-20230159491-A1 Antimicrobial Compounds and Methods NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-25 — — US disclosed
US-11649222-B2 Compounds UNIVERSITETET I OSLO (NO) 2023-05-16 — — US disclosed
US-11649222-B2 Compounds UNIVERSITETET I OSLO (NO) 2023-05-16 — — US disclosed
CN-116059390-A Prodrugs of cytotoxic actives with enzymatically cleavable groups 拜耳制药股份公司 2023-05-05 — — CN disclosed
EP-3978488-A1 ZINC CHELATING COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTION Universitetet I Oslo (NO) 2022-04-06 — — EP disclosed
EP-3978488-A1 ZINC CHELATING COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTION Universitetet I Oslo (NO) 2022-04-06 — — EP disclosed
CN-109952297-B Compound (I) 奥斯陆大学 2022-02-25 — — CN disclosed
EP-3497095-B1 ZINC CHELATING COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTION UNIV OSLO (NO) 2021-07-14 — — EP disclosed
US-20210163458-A1 NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE SANOFI SA (FR) 2021-06-03 — — US disclosed
US-10961223-B2 Compounds UNIVERSITETET I OSLO (NO) 2021-03-30 — — US disclosed
WO-2020150385-A1 ANTIMICROBIAL COMPOUNDS AND METHODS CURZA GLOBAL, LLC (US) 2020-07-23 — — WO disclosed
US-20190284167-A1 COMPOUNDS UNIVERSITETET I OSLO (NO) 2019-09-19 — — US disclosed
US-20190077752-A1 PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-03-14 — — US disclosed
CN-108883195-A Prodrugs of cytotoxic active substances with enzymatically cleavable groups 拜耳制药股份公司 2018-11-23 — — CN disclosed
WO-2018033719-A1 COMPOUNDS UNIVERSITETET I OSLO (NO) 2018-02-22 — — WO disclosed
US-8741834-B2 Dipeptoid prodrugs and the use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-06-03 — — US disclosed
US-20110294719-A1 DIPEPTOID PRODRUGS AND THE USE THEREOF Bayer Schering Pharma 2011-12-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210163458-A1 NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE XPOT, HCCS, COIL KMT2A 3106/4885CTSK 2708/4885CTSS 2179/4885
US-20230159491-A1 Antimicrobial Compounds and Methods MPO, NISCH, RPN2 KMT2A 4067/4885CTSK 151/4885CTSS 112/4885
US-11685714-B2 Prodrugs of cytotoxic active agents having enzymatically cleavable groups BUB1B, KIF5B, TK1 KMT2A 2705/4885CTSK 378/4885CTSS 280/4885
US-20110294719-A1 DIPEPTOID PRODRUGS AND THE USE THEREOF DPP4, DPP3, DNPEP KMT2A 3242/4885CTSK 3343/4885CTSS 4178/4885
US-20240043379-A1 PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS BUB1B, KIF5B, TK1 KMT2A 2705/4885CTSK 378/4885CTSS 280/4885
US-11649222-B2 Compounds SLC30A6, SLC39A11, SLC39A3 KMT2A 2309/4885CTSK 552/4885CTSS 187/4885
US-10961223-B2 Compounds SLC30A6, SLC39A11, SLC30A5 KMT2A 2084/4885CTSK 588/4885CTSS 185/4885
US-20190077752-A1 PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS BUB1B, KIF5B, TK1 KMT2A 2705/4885CTSK 378/4885CTSS 280/4885
US-20190284167-A1 COMPOUNDS SLC30A6, SLC39A11, SLC30A5 KMT2A 2084/4885CTSK 588/4885CTSS 185/4885
US-12503452-B2 Antimicrobial compounds and methods MPO, NISCH, RPN2 KMT2A 4067/4885CTSK 151/4885CTSS 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.